Home Alzheimer’s Disease Specific Racial, Socioeconomic Factors Associated with Improved Survival Rates for Patients with...

Specific Racial, Socioeconomic Factors Associated with Improved Survival Rates for Patients with LS-SCLC

According to a recent study, specific racial and socioeconomic factors were associated with better survival rates for patients with limited-stage small cell lung cancer (LS-SCLC), with African American and Asian patients having better survival rates than White patients after adjusting for sociodemographic factors.

The data, published in JAMA Network Open, also highlighted that, among other things, female sex, higher income, higher education, private insurance, and diagnosis at earlier stages of the disease were all associated with better survival rates for patients of this cancer type.

“The findings of this cohort study suggest that race is associated with survival of L[S]-SCLC, because Asian and African American patients had better survival compared with White patients,” wrote the investigators. “In addition, our results confirmed that female sex, higher median annual income,…

Continue Reading to the Source

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Most Popular

Robert J. Motzer, MD, on Outcomes of the Phase 3 CheckMate 9ER Trial in Advanced RCC

According to results of a subgroup analysis from the phase 3 CheckMate 9ER trial (NCT03141177) presented at the American Society of Clinical Oncology (ASCO)...

Patients Aged 70 or Older With Esophageal or EGJ Cancers Should Be Evaluated for Optimal Curative Therapy

Older patients with locoregional esophageal or esophagogastric junction (EGJ) cancer need to be evaluated for optimal curative therapy, including neoadjuvant chemoradiotherapy and surgical resection,...

Third COVID-19 Vaccine Earns Emergency Use Authorization Following Favorable Advisory Committee Meeting

The first single-dose COVID-19 vaccine was granted Emergency Use Authorization (EUA) by the FDA, according to its developer Janssen Pharmaceutical Companies of Johnson &...

Abiraterone Acetate, Apalutamide Likeliest to Improve Survival for Patients with Castration-Sensitive Prostate Cancer

In a comparison of systemic treatments as add-ons to androgen-deprivation therapy (ADT) for patients with metastatic castration-sensitive prostate cancer (mCSPC), abiraterone acetate (Zytiga) and...

Recent Comments